Brief: Revelation Biosciences Announces Topline Data For Phase 1B Clear Clinical Study Of Revtx-99B For Treatment Of Allergic Rhinitis
22/07/2022 23:31
July 22 (Reuters) - Revelation Biosciences Inc REVB.O :
* . ANNOUNCES TOPLINE DATA FOR PHASE 1B CLEAR CLINICAL STUDY
OF
REVTX-99B FOR THE TREATMENT OF ALLERGIC RHINITIS
* SAYS EXPLORATORY ENDPOINTS FOR EFFICACY WERE NOT MET.
* PRIMARY ENDPOINT TO EVALUATE EFFECTS OF REVTX-99B VERSUS
PLACEBO
ON SAFETY AND TOLERABILITY WAS MET
Source text for Eikon: ID:nGNX4q13Sg
Further company coverage: REVB.O
((Reuters.Briefs@thomsonreuters.com;))